Compare BNZI & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BNZI | TCRT |
|---|---|---|
| Founded | 2016 | 1998 |
| Country | United States | United States |
| Employees | 34 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7M | 6.7M |
| IPO Year | N/A | 2025 |
| Metric | BNZI | TCRT |
|---|---|---|
| Price | $3.49 | $2.83 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $24.00 | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 13.1K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 24.66 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,900,000.00 |
| Revenue This Year | $41.28 | N/A |
| Revenue Next Year | $0.92 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.20 | $1.67 |
| 52 Week High | $8.10 | $5.48 |
| Indicator | BNZI | TCRT |
|---|---|---|
| Relative Strength Index (RSI) | 52.00 | 57.39 |
| Support Level | $0.84 | $2.39 |
| Resistance Level | $3.51 | $2.85 |
| Average True Range (ATR) | 1.06 | 0.18 |
| MACD | -0.22 | 0.06 |
| Stochastic Oscillator | 5.56 | 68.35 |
Banzai International Inc is a Software as a Service (SaaS) company operating in the marketing technology (MarTech) industry. The group provides customers with tools to help them market and sell with greater efficiency and impact. Its customers include Amazon, Dell, Salesforce, Aflac, Thermo Fisher Scientific, RBC Wealth Management, Fitch Group, and many other brands. The Company has three reportable operating segments: Banzai Operating Co, Inc., OpenReel, and Vidello. Its segments deliver SaaS tools that leverage data, analytics, and AI to provide marketing and sales solutions, including video production and editing, for businesses of all sizes. Geographically, it operates in the Americas, Europe, the Middle East and Africa (EMEA), and the Asia Pacific.
Alaunos Therapeutics Inc is a preclinical stage obesity and metabolic health drug development company that is aiming to develop a small molecule-based drug to treat obesity and other metabolic disorders that have a differentiated profile relative to currently marketed and in development oral and injectable products. The company focuses on evaluating the impact of ALN1001, its primary program, and its derivatives on lipid deposition and gene expression. It aims to develop an oral obesity compound that addresses many of the shortcomings of injectable GLP-1 receptor agonists including preserving lean muscle mass.